Correspondence 0001104659-26-057277 from Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc.
Date: May 7, 2026 · CIK: 0001736243 · Accession: 0001104659-26-057277
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295528
Letter
Acurx Pharmaceuticals, Inc.
259 Liberty Avenue Staten Island, New York 10305
May 7, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re: Acurx Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-295528
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Acurx Pharmaceuticals, Inc. (the "Registrant") hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-295528), so that it may become effective at 4:01 p.m. (Washington, D.C. time) on May 11, 2026, or as soon thereafter as practicable.
Please call Ivan K. Blumenthal or Jeffrey D. Cohan of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6784 or (212) 692-6710 with any comments or questions regarding this matter.
Very truly yours,
Acurx Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 May 7, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-295528 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Acurx Pharmaceuticals, Inc. (the "Registrant") hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-295528), so that it may become effective at 4:01 p.m. (Washington, D.C. time) on May 11, 2026, or as soon thereafter as practicable. Please call Ivan K. Blumenthal or Jeffrey D. Cohan of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6784 or (212) 692-6710 with any comments or questions regarding this matter. Very truly yours, Acurx Pharmaceuticals, Inc. By: /s/ David P. Luci Name: David P. Luci Title: President and Chief Executive Officer cc: Acurx Pharmaceuticals, Inc. David P. Luci Robert G. Shawah Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Ivan K. Blumenthal, Esq. Jeffrey D. Cohan, Esq.